Claims for Patent: 11,806,428

Summary for Patent: 11,806,428

Title:	Intranasal pharmaceutical dosage forms comprising naloxone
Abstract:	The present invention relates to an intranasal pharmaceutical dosage form comprising a dosing unit comprising naloxone or a pharmaceutically acceptable salt thereof in an amount of equivalent to ≥0.5 mg naloxone HCl dissolved in an application fluid of a volume of ≤250 μl. Furthermore, the present invention relates to such an intranasal pharmaceutical dosage form for use in the treatment of opioid overdosing and/or at least one symptom thereof.
Inventor(s):	John Strang, Alexander Oksche, Stephen Harris, Kevin Smith, Lucie Helene Jeanne Mottier
Assignee:	Harm Reduction Therapeutics Inc
Application Number:	US17/238,509
Patent Claims:	1. An intranasal pharmaceutical dosage form comprising naloxone or a pharmaceutically acceptable salt thereof dissolved in an application fluid in a final concentration equivalent to between 13 mg naloxone HCl per ml application fluid and 66 mg naloxone HCl per ml application fluid. 2. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 20 mg naloxone HCl per ml application fluid and 60 mg naloxone HCl per ml application fluid. 3. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 20 mg naloxone HCl per ml application fluid and 50 mg naloxone HCl per ml application fluid. 4. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 18 mg naloxone HCl per ml application fluid and 20 mg naloxone HCl per ml application fluid. 5. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to between 13 mg naloxone HCl per ml application fluid and 16 mg naloxone HCl per ml application fluid. 6. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 66 mg naloxone HCl per ml application fluid. 7. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 40 mg naloxone HCl per ml application fluid. 8. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 20 mg naloxone HCl per ml application fluid. 9. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 15 mg naloxone HCl per ml application fluid. 10. The intranasal pharmaceutical dosage form of claim 1, wherein the final concentration of the naloxone or pharmaceutically acceptable salt thereof is equivalent to 13 mg naloxone HCl per ml application fluid. 11. The intranasal pharmaceutical dosage form of claim 1, wherein the application fluid is water or an aqueous saline solution. 12. The intranasal pharmaceutical dosage form of claim 1, wherein the dosage form is provided in a single dosing unit or two dosing units, dependent on whether the dosage form is provided by administration to one nostril or by administration to two nostrils. 13. The intranasal pharmaceutical dosage form of claim 1, wherein the dosage form is a nasal spray, a nasal mucoadhesive dosage form, or a mucosal atomizer device. 14. The intranasal pharmaceutical dosage form of claim 1, wherein the naloxone or pharmaceutically acceptable salt thereof is the only pharmaceutically active compound in the dosage form. 15. The intranasal pharmaceutical dosage form of claim 1, wherein the volume of the dosage form is from 100 μl to about 150 μl. 16. The intranasal pharmaceutical dosage form of claim 1, wherein the dosage form has a pH of ≤5.5. 17. He intranasal pharmaceutical dosage form of claim 1, wherein the dosage form does not include a permeability enhancer. 18. The intranasal pharmaceutical dosage form of claim 1, wherein the application fluid is aqueous saline solution. 19. The intranasal pharmaceutical dosage form of claim 1, that provides a metered volume of nasal spray. 20. The intranasal pharmaceutical dosage form of claim 19, wherein the metered volume is about 100 μl. 21. The intranasal pharmaceutical dosage form of claim 1, wherein the volume of the dosage form is from about 100 μl to about 125 μl; wherein the dosage form has a pH of ≤5.5; wherein the dosage form does not include a permeability enhancer; wherein the application fluid is aqueous saline solution; and wherein the dosage form provides a metered nasal spray in a volume of about 100 μl. 22. The intranasal pharmaceutical dosage form of claim 3, wherein the volume of the dosage form is from about 100 μl to about 125 μl. 23. The intranasal pharmaceutical dosage form of claim 3, wherein the dosage form has a pH of ≤5.5. 24. The intranasal pharmaceutical dosage form of claim 3, wherein the dosage form does not include a permeability enhancer. 25. The intranasal pharmaceutical dosage form of claim 3, wherein the application fluid is aqueous saline solution. 26. The intranasal pharmaceutical dosage form of claim 3, that provides a metered volume of nasal spray. 27. The intranasal pharmaceutical dosage form of claim 26, wherein the metered volume is about 100 μl. 28. The intranasal pharmaceutical dosage form of claim 3, wherein the volume of the dosage form is from about 100 μl to about 125 μl; wherein the dosage form has a pH of ≤5.5; wherein the dosage form does not include a permeability enhancer; wherein the application fluid is aqueous saline solution; and wherein the dosage form provides a metered nasal spray in a volume of about 100 μl. 29. The intranasal pharmaceutical dosage form of claim 7, wherein the volume of the dosage form is from about 100 μl to about 125 μl. 30. The intranasal pharmaceutical dosage form of claim 7, wherein the dosage form has a pH of ≤5.5. 31. The intranasal pharmaceutical dosage form of claim 7, wherein the dosage form does not include a permeability enhancer. 32. The intranasal pharmaceutical dosage form of claim 7, wherein the application fluid is aqueous saline solution. 33. The intranasal pharmaceutical dosage form of claim 7, that provides a metered volume of nasal spray. 34. The intranasal pharmaceutical dosage form of claim 33, wherein the metered volume is about 100 μl. 35. The intranasal pharmaceutical dosage form of claim 7, wherein the volume of the dosage form is from about 100 μl to about 125 μl; wherein the dosage form has a pH of ≤5.5; wherein the dosage form does not include a permeability enhancer; wherein the application fluid is aqueous saline solution; and wherein the dosage form provides a metered nasal spray in a volume of about 100 μl.